Brazilian IBD patients under the microscope: how long do they stay on treatment?
NCT ID NCT05626088
First seen Jun 25, 2026 · Last updated Aug 07, 2026 · Updated 2 times
Summary
This study observes 1006 adults with ulcerative colitis or Crohn's disease in Brazil who are taking or have taken vedolizumab. Researchers will look at how long patients stay on the drug and what other treatments they used before. No new treatment is given—this is just a review of existing data from a patient support program.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CROHN'S DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Pesquisare Saúde S/S Ltda
Santo André, São Paulo, 09080-001, Brazil
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Sound waves vs. scope: a gentler way to spot pouch inflammation?
- Can we predict how kids with IBD will respond to treatment?
- AI reads scans to forecast Crohn's complications
- Can stem cell vesicles heal Crohn's fistulas?
- Can a new drug calm the Gut's overactive immune response in Crohn's?
- Can switching IBD meds heal the gut when symptoms are quiet?